References
- Blaivas JG, Groutz A. Urinary incontinence: pathophysiology, evaluation and management overview In: Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ. Campbell's urology, 8th ed. Philadelphia, PA: W. B. Saunders; 2002. p. 1027–52.
- Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder Urology 2000;55, (, 5A Suppl ):33–46.
- Schurch B, Störer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-a toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164: 692–7
- Bagi P, Biering-Sørensen F. Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand J Urol Nephrol 2004; 38: 495–8
- Reitz A, Stöhrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, et al. European experience of 200 cases treated with Botulinum-a toxin injections in the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004; 45: 510–5
- Kessler TM, Danuser H, Schumacher M, Studer UE, Burkhard FC. Botulinum-A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity?. Neurourol Urodyn 2005; 24: 231–6
- Schurch B, de Sèze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. on behalf of the Botox® detrusor hyperreflexia study team. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005; 174: 196–200
- Costa P, Perrouin-Verbe B, Colvez A, Didier JP, Marquis P, Marrel A, et al. Quality of life in spinal cord injured patients with urinary difficulties. Development and validation of Qualiveen. Eur Urol 2001; 39: 107–13
- Wein AJ. Neuromuscular dysfunction of the lower urinary tract and its management In: Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ Campbell's urology, 8th ed. Philadelphia, PA: W. B. Saunders; 2002. p. 931–1026.
- Grosse JO, Kramer AEJL, Loechner-Ernst D, Stöhrer M. Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005; 47: 653–9
- Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CF, Dasgupta P. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of Botulinum-A toxin. J Urol 2005; 174: 984–9
- Dolly O. Synaptic transmission; inhibition of neurotransmitter release by botulinum toxins. Headache 2003; 43(Suppl 1)16–24
- Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibres following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005; 174: 977–82
- Rajkumar GN, Small DR, Mustafa AW, Conn G. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical botulinum toxin A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. Br J Urol 2005; 96: 848–52